Abstract:One of the pathogenesis hypotheses of Alzheimer's disease (AD) is amyloid depositions and neurofibrillary tangles. Apolipoprotein E (Apo E) acts a vital part in the development of AD by affecting the aggregation and clearance of amyloid-β (Aβ). In this paper, a dual polarization interferometry (DPI) technique was employed for a real-time investigation toward the binding events of Apo E isoforms, for instance, Apo E2, Apo E3, and Apo E4, with Aβ1–40. By evaluation of detailed binding information provided by DPI, the affinities between Apo E isoforms and Aβ1–40 follow the order of E4 > E3 > E2, and the dissociation constants (KD) of Aβ1–40 with Apo E2, Apo E3, and Apo E4 were determined to be 251 ± 37, 40 ± 0.65, and 24.6 ± 2.42 nM, respectively. Our findings reveal the isoform-specific binding behaviors from a kinetics perspective, which can help us understand that Apo E4 has a higher risk of causing AD because of its promoting effect on Aβ aggregation and fibrillation and inefficient clearance of Aβ. Remarkably, this work provides a promising method for exploring the dynamics of interactions between biomolecules and expectantly contributes to the development of AD drugs and therapies targeting Apo E and Aβ.The Supporting Information is available free of charge at <a class="ext-link" href="/doi/10.1021/acs.analchem.0c03542?goto=supporting-info">https://pubs.acs.org/doi/10.1021/acs.analchem.0c03542</a>.Real-time thickness and density changes of the interactions of the Aβ1–40 peptide with Apo E isoforms (Figure S1); differential CD spectra of Apo E2 and Apo E3 in the presence of Aβ1–40 peptide with different concentrations (Figure S2); regeneration plot of the sensing surface (Figure S3); purities of all the peptides used in the study (Table S1); mass spectrum analysis of Aβ1–40 peptide (Figure S4); HPLC and SDS-PAGE analysis of Apo E2 (Figure S5); the SDS-PAGE analysis of Apo E3 (Figure S6); and HPLC and SDS-PAGE analysis of Apo E4 (Figure S7) (<a class="ext-link" href="/doi/suppl/10.1021/acs.analchem.0c03542/suppl_file/ac0c03542_si_001.pdf">PDF</a>)This article has not yet been cited by other publications.

Mapping ApoE/Aβ binding regions to guide inhibitor discovery.

Inhibitor discovery targeting the intermediate structure of beta-amyloid peptide on the conformational transition pathway: implications in the aggregation mechanism of beta-amyloid peptide.

Inhibitor discovery targeting the intermediate structure of β-amyloid peptide on the conformational transition pathway: Implications in the aggregation mechanism of β-amyloid peptide

A Novel Apolipoprotein E Antagonist Functionally Blocks Apolipoprotein E Interaction with N-terminal Amyloid Precursor Protein, Reduces Β-Amyloid-associated Pathology, and Improves Cognition

Progress in the Development of Nonpeptidomimetic BACE 1 Inhibitors for Alzheimers Disease

A Biophysical Approach to the Identification of Novel ApoE Chemical Probes

Identification Of Novel Bace1 Inhibitors By Combination Of Pharmacophore Modeling, Structure-Based Design And In Vitro Assay

Targeting of Nonlipidated, Aggregated Apoe with Antibodies Inhibits Amyloid Accumulation

Real-Time Analysis of Specific Binding between Apolipoprotein E Isoforms and Amyloid β-Peptide by Dual Polarization Interferometry

Aβ20–29 Peptide Blocking Apoe/aβ Interaction Reduces Full-Length Aβ42/40 Fibril Formation and Cytotoxicity in Vitro

Atomistic Characterization of Binding Modes and Affinity of Peptide Inhibitors to Amyloid-Β Protein

Aβ-binding molecules: Possible application as imaging probes and as anti-aggregation agents

Apolipoprotein E in Alzheimer’s Disease: Focus on Synaptic Function and Therapeutic Strategy

Apolipoprotein E in Alzheimer's Disease: Focus on Synaptic Function and Therapeutic Strategy

ApoE and Aβ in Alzheimer's Disease: Accidental Encounters or Partners?

Targeting Amyloidogenic Processing of APP in Alzheimer’s Disease

A Beta-Binding Molecules: Possible Application As Imaging Probes And As Anti-Aggregation Agents

Design, synthesis and biological evaluation of novel dual inhibitors of acetylcholinesterase and beta-secretase

Effects of Anti-ApoE on Blocking the ApoE/Aβ Interaction and Reducing Aβ1-42 Aggregation and Fibrillization

Discovery and Biological Evaluation of New Selective Acetylcholinesterase Inhibitors with Anti-Aβ Aggregation Activity Through Molecular Docking-Based Virtual Screening.

Biomimetic ApoE-Reconstituted High Density Lipoprotein Nanocarrier for Blood-Brain Barrier Penetration and Amyloid Beta-Targeting Drug Delivery.